Over 114 thousand coronavirus infections worldwide, including over 4,000 fatalities. These numbers work on the imagination. The first company to launch an effective SARS-CoV-2 vaccine will make a fortune.
That is why biotechnology companies decide to use controversial strategies. The British hVIVO offers, for example, 3,500 pounds (17,000 zlotys) to volunteers who voluntarily agree to be infected with their coronavirus.
In this way, the British want to test SARS-CoV-2 much more accurately than standard laboratory procedures would allow. For this they want to test several experimental drugs on volunteers. The sooner the results of these tests can be obtained, the greater the chance that hVIVO will make a lot of money. The UK government will gladly pay for the coronavirus problem that has been studied and successfully resolved.
Americans already have the vaccine
It is mRNA-1273 , a vaccine developed by the biotechnology company Moderna, which announced that the first batch of their product has already been sent to the National Institute of Allergy and Infectious Diseases (NIAID) in the United States.
This lot will be used in the phase 1 study, which means it will be given to a small group of healthy people. This is done to see if mRNA-1273 will trigger the desired response from the immune system, which, when activated, will protect the body against coronavirus infection.
The vaccine was designed with the virus proteins responsible for infecting human cells in mind. If everything goes according to plan, the immune system of vaccinated people evolve in advance corresponding antibodies, so that SARS-CoV-2 will not be able to attach to the man.
Another issue is when it appears on the market.
Moderna admitted that she already has the vaccine ready for the first phase of testing. It is not known, however, whether mRNA-1273 will pass through it successfully. Therefore, the race is not over yet, and work in the laboratories of biotechnology companies from around the world is booming.
We have a Polish accent here. It is about the company KO-MED Clinical Centers from the Lublin region, which has just started cooperation with the American Medical College of Wisconsin, in the laboratories of which the coronavirus vaccine is also being created.
The task of the Polish company will be to conduct its clinical tests. It cannot be ruled out that Poland will be one of the first countries on our continent to find a solution to the coronavirus problem.
Coronavirus vaccine - biotech companies from all over the world are on the race
Comments
Post a Comment